iBio, Inc.
IBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001420720
No open-market purchases or sales by iBio, Inc. insiders were filed in the last 90 days; 55 institutions reported holding it in 13F filings for Q2 2026, worth $60.8M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in iBio, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 28
- +7 vs. Q4 2023
- Shares held
- 2.89M
- +2.63M (+1,047.4%) vs. Q4 2023
- Total value
- $11.5M
- +$11.1M (+3,228.5%) vs. Q4 2023
- New holders
- 10
- 5 more added
- Sold out
- 3
- 5 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IBIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 55 | $60.8M |
| Q1 2026 | 52 | $36.9M |
| Q4 2025 | 50 | $31.6M |
| Q3 2025 | 32 | $2.96M |
| Q2 2025 | 30 | $2.44M |
| Q1 2025 | 34 | $10.4M |
| Q4 2024 | 30 | $6.40M |
| Q3 2024 | 32 | $5.79M |
| Q2 2024 | 28 | $5.68M |
| Q1 2024 | 28 | $11.5M |
| Q4 2023 | 21 | $344.6K |
| Q3 2023 | 29 | $269.9K |
| Q2 2023 | 29 | $695.7K |
| Q1 2023 | 30 | $3.45M |
| Q4 2022 | 38 | $1.02M |
| Q3 2022 | 46 | $4.97M |
| Q2 2022 | 57 | $7.63M |
| Q1 2022 | 77 | $17.5M |
| Q4 2021 | 83 | $25.0M |
| Q3 2021 | 90 | $47.6M |
| Q2 2021 | 87 | $65.5M |
| Q1 2021 | 94 | $68.5M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding iBio, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Opaleye Management Inc. | 680,000 | $2.76M | 0.60% | +680,000 | New |
| Ikarian Capital, LLC | 600,000 | $2.44M | 0.66% | +600,000 | New |
| Lynx1 Capital Management LP | 600,000 | $2.44M | 0.63% | +600,000 | New |
| ADAR1 Capital Management, LLC | 600,000 | $2.19M | 0.60% | +600,000 | New |
| Armistice Capital, LLC | 350,877 | $1.42M | 0.04% | +350,877 | New |
| Renaissance Technologies LLC | 15,879 | $64.0K | 0.00% | +15,879 | New |
| Sabby Management, LLC | 14,000 | $56.8K | 0.37% | −162,748−92.1% | Reduced |
| FNY Investment Advisers, LLC | 9,000 | $36.0K | 0.02% | +9,000 | New |
| BlackRock Inc. | 5,815 | $23.6K | 0.00% | −1,072−15.6% | Reduced |
| Tower Research Capital LLC (TRC) | 5,603 | $22.7K | 0.00% | +820+17.1% | Added |
| UBS Group AG | 1,877 | $7.62K | 0.00% | −16,123−89.6% | Reduced |
| IFP Advisors, Inc | 1,000 | $4.06K | 0.00% | +1,000 | New |
| BNP Paribas Arbitrage, SA | 502 | $2.04K | 0.00% | +502 | New |
| Morgan Stanley | 268 | $1.09K | 0.00% | −71−20.9% | Reduced |
| Group One Trading, L.P. | 161 | $654 | 0.00% | +111+222.0% | Added |
| Citigroup Inc | 161 | $654 | 0.00% | +119+283.3% | Added |
| Advisor Group Holdings, Inc. | 58 | $234 | 0.00% | 00.0% | Unchanged |
| Harbour Investments, Inc. | 40 | $162 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 28 | $114 | 0.00% | +16+133.3% | Added |
| Retirement Group, LLC | 14 | $57 | 0.00% | 00.0% | Unchanged |
| SOA Wealth Advisors, LLC. | 13 | $53 | 0.00% | 00.0% | Unchanged |
| City Holding Co | 4 | $16 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 4 | $16 | 0.00% | +4 | New |
| Steward Partners Investment Advisory, LLC | 3 | $12 | 0.00% | 00.0% | Unchanged |
| Sofos Investments, Inc. | 4 | $11 | 0.00% | +2+100.0% | Added |
| JPMorgan Chase & Co | 2 | $8 | 0.00% | 00.0% | Unchanged |
| SRS Capital Advisors, Inc. | 1 | $5 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 52 | $0 | 0.00% | −26−33.3% | Reduced |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −25,387−100.0% | Sold out |
| Warberg Asset Management LLC | 0 | $0 | 0.00% | −19,000−100.0% | Sold out |
| Planned Solutions, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |